COLCOT: Low-dose colchicine reduces CV risk after MI

Well, did your stroke hospital do ONE DAMN THING with this earlier research? If not, what the fuck use is your stroke hospital? Who specifically are they waiting for to solve stroke? Call the president and ask when competent persons will be hired to put stroke research into protocols.

I bet they will incompetently DO NOTHING because it is easier to wait for SOMEONE ELSE TO SOLVE THE PROBLEM?    Fire them all.

• colchicine (4)

COLCOT: Low-dose colchicine reduces CV risk after MI

PHILADELPHIA — Adults with a recent MI were less likely to experience an ischemic CV event over 2 years when assigned the anti-inflammatory gout medication colchicine compared with assignment to placebo, according to new results of the COLCOT trial presented at the American Heart Association Scientific Sessions.
“In addition to standard of care in patients with a recent MI, colchicine 0.5 mg daily significantly reduces the risk for first ischemic CV events by 23% and total ischemic cardiovascular events by 34%,” Jean-Claude Tardif, MD, director of research at the Montreal Heart Institute, told Healio. “By repurposing well-known medications like colchicine, we can help address the major public health issue of subsequent CV events after an MI in a cost-effective manner, to help patients worldwide overcome the cost barriers of their treatment.”

Efficacy, safety
The COLCOT researchers analyzed data from 4,745 adults recruited within 30 days after MI who were randomly assigned colchicine 0.5 mg once daily (n = 2,366) or placebo (n = 2,379) and followed for a median of 22.6 months. The mean age was 61 years, 19% were women and 20% had diabetes.
The primary endpoint — CV death, resuscitated cardiac arrest, MI, stroke or hospitalization for angina leading to coronary revascularization — occurred in 5.5% of participants in the colchicine arm and 7.1% of participants in the placebo arm, for an HR of 0.77 (95% CI, 0.61-0.96).
The researchers observed risk reduction across the five individual endpoints for patients in the colchicine arm: HR = 0.84 for CV death (95% CI, 0.46-1.52), 0.83 for resuscitated cardiac arrest (95% CI, 0.25-2.73), 0.91 for MI (95% CI, 0.68-1.21), 0.26 for stroke (95% CI, 0.1-0.7) and 0.5 for urgent hospitalization for angina (95% CI, 0.31-0.81).
In a per-protocol analysis, the benefits of colchicine were magnified, Tardif said, with a relative risk reduction of 29% for the primary endpoint (HR = 0.71; 95% CI, 0.56-0.9).
Colchicine was well tolerated and there were no between-group differences for adverse events, Tardif said. Rates of diarrhea (9.7% vs. 8.9%; P = .35) and pneumonia (0.9% vs. 0.4%; P = .03) were higher among patients assigned colchicine.
“The magnitude of colchicine's benefits, 23% and 34% for first and total — including recurrent — primary endpoint CV events, on a background of excellent standard of care, is surprising,” Tardif said in an interview. “The excellent tolerability profile of colchicine is also very reassuring.”